Position paper on CDK4/6 inhibitors in early breast cancer

Inhibitors of the cyclin-dependent kinases 4/6 (CDK4/6i) have been practice-changing and are now considered the standard of care in combination with endocrine therapy for the first- or second-line treatment in advanced hormone-receptor-positive, human epidermal growth factor receptor 2‑negative breast cancer. Recently, CDK4/6i have also emerged as an appealing targeted cancer therapy in early breast cancer, however results of large clinical trials are controversial. This position paper summarizes the evidence, and provides guidance for clinical practice.

• Publication year

  2023

• Venue

  memo - Magazine of European Medical Oncology

• Publication date

  2023-03-14

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/s12254-023-00878-1
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).

  2022cited by this paper
• 59MO Adjuvant abemaciclib combined with endocrine therapy (ET): Efficacy results in monarchE cohort 1

  2022cited by this paper
• Adjuvant Abemaciclib Combined with Endocrine Therapy for High Risk Early Breast Cancer: Safety and Patient-Reported Outcomes From the monarchE Study.

  2022cited by this paper
• Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer.

  2022cited by this paper
• Adjuvant abemaciclib for high-risk early breast cancer (EBC): Factors increasing the rate of treatment discontinuations in monarchE.

  2022cited by this paper
• Adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer: ADAPTcycle.

  2022cited by this paper
• Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer

  2022cited by this paper
• Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.

  2022cited by this paper
• Abstract P5-16-12: Neoadjuvant letrozole plus palbociclib in patients (pts) with hormone receptor (HR)-positive/HER2-negative early breast cancer (EBC) with baseline Ki67 ≥20% and an Oncotype DX Breast Recurrence Score® result (RS) ≥18: DxCARTES

  2022cited by this paper
• Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer

  2022cited by this paper
• Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.

  2022cited by this paper
• LBA14 Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study

  2021cited by this paper
• Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

  2021cited by this paper
• Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study.

  2021cited by this paper
• ADAPTlate: A randomized, controlled, open-label, phase III trial on adjuvant dynamic marker—Adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high-risk, HR+/HER2- early breast canc

  2021cited by this paper
• Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial

  2021influential reference
• Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies

  2021cited by this paper
• CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis

  2021cited by this paper
• CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives

  2021cited by this paper
• Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.

  2021influential reference
• PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients.

  2020cited by this paper
• Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials

  2020cited by this paper
• CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer

  2020cited by this paper
• Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial

  2020cited by this paper
• Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences

  2020influential reference
• CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?

  2020cited by this paper
• Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).

  2020cited by this paper
• Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

  2019cited by this paper
• Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review

  2019cited by this paper
• MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

  2019cited by this paper
• Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer

  2019cited by this paper
• Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

  2019cited by this paper
• NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) early breast cancer (EBC).

  2019influential reference
• Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer

  2019cited by this paper
• Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.

  2019cited by this paper
• Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.

  2018cited by this paper
• Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.

  2018influential reference
• The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

  2018cited by this paper
• Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

  2018cited by this paper
• The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.

  2018cited by this paper
• De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

  2018cited by this paper
• NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer

  2017cited by this paper
• Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict’s value

  2017cited by this paper
• CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers

  2017cited by this paper
• Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial

  2017influential reference
• Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.

  2016cited by this paper
• Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance

  2016cited by this paper
• Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

  2016cited by this paper
• Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence

  2016cited by this paper
• A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer

  2016cited by this paper
• Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole

  2016cited by this paper
• 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

  2016cited by this paper
• Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

  2015cited by this paper
• Defining breast cancer intrinsic subtypes by quantitative receptor expression.

  2015cited by this paper
• The history and future of targeting cyclin-dependent kinases in cancer therapy

  2015cited by this paper
• Comprehensive molecular portraits of human breast tumours

  2013cited by this paper
• Comprehensive molecular portraits of human breast tumors

  2012cited by this paper
• The molecular profile of luminal B breast cancer

  2012cited by this paper
• Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.

  2012cited by this paper
• Repeated observation of breast tumor subtypes in independent gene expression data sets

  2003cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper

• Real-World Analysis of Adherence to Abemaciclib and Endocrine Therapy in Women with HR+/HER2− Breast Cancer

  2025influential citation
• Clinician’s guide: expert insights on the use of CDK4/6 inhibitors in patients with early breast cancer

  2025influential citation
• Impact of Patient Profile on CDK4/6 Inhibitor Therapy Outcomes: A Real-World Data Analysis

  2025cites this paper